Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69,586 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, Chen X, Hu Y, Liu X, Jiang C, Li J, Yang M, Song Y, Wang X, Gao Q, Zhu F. Zhang Y, et al. Among authors: chen z, chen x. Lancet Infect Dis. 2021 Feb;21(2):181-192. doi: 10.1016/S1473-3099(20)30843-4. Epub 2020 Nov 17. Lancet Infect Dis. 2021. PMID: 33217362 Free PMC article. Clinical Trial.
Safety, immunogenicity, and lot-to-lot consistency of live attenuated varicella vaccine in 1-3 years old children: a double-blind, randomized phase III trial.
Huang L, Chen Z, Hu Y, Xie Z, Qiu P, Zhu L, Bao M, Quan Y, Zeng J, Wang Y, Cui X, Yuan L, Xia S, Meng F. Huang L, et al. Among authors: chen z. Hum Vaccin Immunother. 2019;15(4):822-827. doi: 10.1080/21645515.2018.1551701. Epub 2019 Jan 24. Hum Vaccin Immunother. 2019. PMID: 30481106 Free PMC article. Clinical Trial.
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, Li M, Jin H, Cui G, Chen P, Wang L, Zhao G, Ding Y, Zhao Y, Yin W. Wu Z, et al. Among authors: chen z, chen p. Lancet Infect Dis. 2021 Jun;21(6):803-812. doi: 10.1016/S1473-3099(20)30987-7. Epub 2021 Feb 3. Lancet Infect Dis. 2021. PMID: 33548194 Free PMC article. Clinical Trial.
Safety and immunogenicity of a skin- and neuro-attenuated live vaccine for varicella: a randomized, double-blind, controlled, dose-escalation and age de-escalation phase 1 clinical trial.
Mo ZJ, Huang SJ, Qiu LX, Li CG, Yu XJ, Li MQ, Chen Z, Zhong GH, Pan DQ, Huang LR, Lv BJ, Cui XL, Song QQ, Jia JZ, Han JL, Wang W, Zhu H, Cheng T, Su YY, Li YM, Ye XZ, Wu T, Zhang J, Xia NS. Mo ZJ, et al. Among authors: chen z. Lancet Reg Health West Pac. 2023 Feb 18;34:100707. doi: 10.1016/j.lanwpc.2023.100707. eCollection 2023 May. Lancet Reg Health West Pac. 2023. PMID: 37283962 Free PMC article.
Immunogenicity and safety of an ORF7-deficient skin-attenuated and neuro-attenuated live vaccine for varicella: a randomised, double-blind, controlled, phase 2a trial.
Pan HX, Qiu LX, Liang Q, Chen Z, Zhang ML, Liu S, Zhong GH, Zhu KX, Liao MJ, Hu JL, Li JX, Xu JB, Fan Y, Huang Y, Su YY, Huang SJ, Wang W, Han JL, Jia JZ, Zhu H, Cheng T, Ye XZ, Li CG, Wu T, Zhu FC, Zhang J, Xia NS. Pan HX, et al. Among authors: chen z. Lancet Infect Dis. 2024 Apr 10:S1473-3099(24)00159-2. doi: 10.1016/S1473-3099(24)00159-2. Online ahead of print. Lancet Infect Dis. 2024. PMID: 38614117
Characterization of humoral immune responses against SARS-CoV-2 accessory proteins in infected patients and mouse model.
Li Y, Tang Y, Wang X, Zhu A, Liu D, He Y, Guo H, Zheng J, Liu X, Chi F, Wang Y, Zhuang Z, Zhang Z, Liu D, Chen Z, Li F, Ran W, Yu K, Wang D, Wen L, Zhuo J, Zhang Y, Xi Y, Zhao J, Zhao J, Sun J. Li Y, et al. Among authors: chen z. Virol Sin. 2024 Apr 25:S1995-820X(24)00061-0. doi: 10.1016/j.virs.2024.04.005. Online ahead of print. Virol Sin. 2024. PMID: 38677713
69,586 results
You have reached the last available page of results. Please see the User Guide for more information.